Tag: axillaryNodeDissection

News

09/16/12

Axillary node dissection unnecessary for some despite micrometastases

10/03/10

Lobular breast cancer micrometastases may be classified incorrectly

02/28/10

Does air travel increase lymphedema in breast cancer survivors?

Studies

• Is routine axillary staging still required in clinically node negative early breast cancer in women over 74 years? Cite
  Grant K, Po XY, Tiong L. Is routine axillary staging still required in clinically node negative early breast cancer in women over 74 years?. ANZ Journal of Surgery. Wiley; 2024; 10.1111/ans.19313
• A Prospective Study of Sentinel Node Biopsy Omission in Women Age ≥ 65 Years with ER+ Breast Cancer Cite
  Chung AP, Dang CM, Karlan SR, Amersi FF, Phillips EM, Boyle MK, et al. A Prospective Study of Sentinel Node Biopsy Omission in Women Age ≥ 65 Years with ER+ Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-15000-w
• Axillary Lymph Node Dissection is Associated with Improved Survival Among Men with Invasive Breast Cancer and Sentinel Node Metastasis Cite
  Chung SH, de Geus SWL, Shewmaker G, Romatoski KS, Drake FT, Ko NY, et al. Axillary Lymph Node Dissection is Associated with Improved Survival Among Men with Invasive Breast Cancer and Sentinel Node Metastasis. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-13475-7
• Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer Cite
  Ye L, Rünger D, Angarita SA, Hadaya J, Baker JL, Lee MK, et al. Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06581-9
• Can We Successfully De-Escalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy? Cite
  Matar R, Barrio AV, Sevilimedu V, Le T, Heerdt A, Morrow M, et al. Can We Successfully De-Escalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-021-11140-5
• Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy Cite
  McKevitt E, Cheifetz R, DeVries K, Laws A, Warburton R, Gondara L, et al. Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-09839-6
• Long-term outcome and axillary recurrence in elderly women (≥70 years) with breast cancer: 10-years follow-up from a matched cohort study Cite
  Corso G, Magnoni F, Montagna G, Maisonneuve P, Polizzi A, Massari G, et al. Long-term outcome and axillary recurrence in elderly women (≥70 years) with breast cancer: 10-years follow-up from a matched cohort study. European Journal of Surgical Oncology. Elsevier BV; 2021; 10.1016/j.ejso.2021.02.027
• Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? Cite
  Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, et al. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:4603-4612 10.1245/s10434-020-08891-y
• The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer Cite
  Grova MM, Strassle PD, Navajas EE, Gallagher KK, Ollila DW, Downs-Canner SM, et al. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 10.1245/s10434-020-09152-8
• Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy Cite
  Samiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS, et al. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2020; 271:574-580 10.1097/sla.0000000000003126
• De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study Cite
  Simons JM, Koppert LB, Luiten EJT, van der Pol CC, Samiei S, de Wilt JHW, et al. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:725-733 10.1007/s10549-020-05589-3
• Nodal positivity decreases with age in women with early‐stage, hormone receptor–positive breast cancer Cite
  Downs‐Canner SM, Gaber CE, Louie RJ, Strassle PD, Gallagher KK, Muss HB, et al. Nodal positivity decreases with age in women with early‐stage, hormone receptor–positive breast cancer. Cancer. Wiley; 2019; 126:1193-1201 10.1002/cncr.32668
• Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers Cite
  Corona SP, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F, et al. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:735-745 10.1007/s10549-020-05565-x
• Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers Cite
  Mamtani A, Zabor EC, Stempel M, Morrow M. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3269-3274 10.1245/s10434-019-07536-z
• The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer Cite
  Poodt IG, Schipper R, Vugts G, Woensdregt K, van der Sangen M, Voogd AC, et al. The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer. European Journal of Surgical Oncology. Elsevier BV; 2018; 44:1714-1719 10.1016/j.ejso.2018.07.005
• Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Cite
  Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:561-564 10.1200/jco.2016.71.0947
• Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis Cite
  Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA. American Medical Association (AMA); 2017; 318:918 10.1001/jama.2017.11470
• Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer Cite
  DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, et al. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2018; 18:e73-e77 10.1016/j.clbc.2017.06.014
• Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study Cite
  de Boniface J, Frisell J, Bergkvist L, Andersson Y. Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study. British Journal of Surgery. Oxford University Press (OUP); 2017; 104:238-247 10.1002/bjs.10411
• Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: A systematic review and meta-analysis Cite
  Liang S, Hallet J, Simpson JS, Tricco AC, Scheer AS. Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: A systematic review and meta-analysis. Journal of Geriatric Oncology. Elsevier BV; 2017; 8:140-147 10.1016/j.jgo.2016.12.003
• Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients Cite
  El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. The American Journal of Surgery. Elsevier BV; 2016; 212:969-981 10.1016/j.amjsurg.2016.07.018
• Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies Cite
  Wang L, Guyatt GH, Kennedy SA, Romerosa B, Kwon HY, Kaushal A, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. Canadian Medical Association Journal. Joule Inc.; 2016; 188:E352-E361 10.1503/cmaj.151276
• Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands Cite
  Vugts G, Maaskant-Braat A, de Roos W, Voogd A, Nieuwenhuijzen G. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:956-964 10.1016/j.ejso.2016.03.023
• The Impact of Axillary Lymph Node Surgery on Breast Skin Thickening During and After Radiation Therapy for Breast Cancer Cite
  Torres MA, Yang X, Noreen S, Chen H, Han T, Henry S, et al. The Impact of Axillary Lymph Node Surgery on Breast Skin Thickening During and After Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2016; 95:590-596 10.1016/j.ijrobp.2016.01.030
• Axillary reverse mapping in patients with breast cancer: Is it oncologically safe? Cite
  Ngui NK, French J, Kilby CJ, Pathmanathan N, Elder EE. Axillary reverse mapping in patients with breast cancer: Is it oncologically safe?. Journal of Surgical Oncology. Wiley; 2016; 113:726-731 10.1002/jso.24231
• Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node vs. Observation after axillary Ultra-souND) trial Cite
  Gentilini O, Botteri E, Dadda P, Sangalli C, Boccardo C, Peradze N, et al. Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node vs. Observation after axillary Ultra-souND) trial. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:685-689 10.1016/j.ejso.2016.01.020
• Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy Cite
  Xin F, Yu Y, Yang Z, Hou L, Mao J, Xia L, et al. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy. Tumor Biology. Springer Science and Business Media LLC; 2016; 37:8445-8454 10.1007/s13277-015-4640-3
• Association between Lymph Node Ratio and Disease Specific Survival in Breast Cancer Patients with One or Two Positive Lymph Nodes Stratified by Different Local Treatment Modalities Cite
  Hong R, Dai Z, Zhu W, Xu B. Association between Lymph Node Ratio and Disease Specific Survival in Breast Cancer Patients with One or Two Positive Lymph Nodes Stratified by Different Local Treatment Modalities. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0138908 10.1371/journal.pone.0138908
• Occult metastases in node-negative breast cancer: A Surveillance, Epidemiology, and End Results−based analysis Cite
  Kimbrough CW, McMasters KM, Quillo A, Ajkay N. Occult metastases in node-negative breast cancer: A Surveillance, Epidemiology, and End Results−based analysis. Surgery. Elsevier BV; 2015; 158:494-500 10.1016/j.surg.2015.03.049
• Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-Year results of trial and out-trial patients Cite
  Martelli G, Boracchi P, Orenti A, Lozza L, Maugeri I, Vetrella G, et al. Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-Year results of trial and out-trial patients. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:805-812 10.1016/j.ejso.2014.03.029
• Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database Cite
  Wang J, Mittendorf EA, Sahin AA, Yi M, Caudle A, Hunt KK, et al. Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e89778 10.1371/journal.pone.0089778
• Upper Limb Physical Function and Adverse Effects After Breast Cancer Surgery: A Prospective 2.5-Year Follow-Up Study and Preoperative Measures Cite
  Sagen A, Kaaresen R, Sandvik L, Thune I, Risberg MA. Upper Limb Physical Function and Adverse Effects After Breast Cancer Surgery: A Prospective 2.5-Year Follow-Up Study and Preoperative Measures. Archives of Physical Medicine and Rehabilitation. Elsevier BV; 2014; 95:875-881 10.1016/j.apmr.2013.12.015
• Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000 Cite
  Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al. Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2012; 20:120-127 10.1245/s10434-012-2569-y
• Effectiveness of Sentinel Lymph Node Intraoperative Examination in 753 Women With Breast Cancer Cite
  Taffurelli M, Montroni I, Santini D, Fiacchi M, Zanotti S, Ugolini G, et al. Effectiveness of Sentinel Lymph Node Intraoperative Examination in 753 Women With Breast Cancer. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2012; 255:976-980 10.1097/sla.0b013e31824def4e
• Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial Cite
  Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens M, Van Limbergen E, et al. Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. The Lancet Oncology. Elsevier BV; 2012; 13:412-419 10.1016/s1470-2045(12)70042-6
• Axillary node staging for microinvasive breast cancer: Is it justified? Cite
  Lyons JM, Stempel M, Van Zee KJ, Cody HS. Axillary node staging for microinvasive breast cancer: Is it justified?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:7-7 10.1200/jco.2011.29.27_suppl.7
• Effect of axillary dissection for occult detected sentinel nodes metastases on survival: NSABP B-32. Cite
  Julian TB, Anderson SJ, Mamounas EP, Krag DN, Weaver D, Ashikaga T, et al. Effect of axillary dissection for occult detected sentinel nodes metastases on survival: NSABP B-32.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:80-80 10.1200/jco.2011.29.27_suppl.80
• Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer Cite
  Wu Y, Mittendorf EA, Kelten C, Tucker SL, Wei W, Middleton LP, et al. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. Wiley; 2011; 118:1507-1514 10.1002/cncr.26458
• Long-term observational follow-up study of breast cancer diagnosed in women ≤40 years old Cite
  Karihtala P, Winqvist R, Bloigu R, Jukkola-Vuorinen A. Long-term observational follow-up study of breast cancer diagnosed in women ≤40 years old. The Breast. Elsevier BV; 2010; 19:456-461 10.1016/j.breast.2010.05.001
• Accurate classification of sentinel lymph node metastases in patients with lobular breast carcinoma Cite
  Apple SK, Moatamed NA, Finck RH, Sullivan PS. Accurate classification of sentinel lymph node metastases in patients with lobular breast carcinoma. The Breast. Elsevier BV; 2010; 19:360-364 10.1016/j.breast.2010.02.010
• Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study Cite
  Maaskant-Braat AJ, van de Poll-Franse LV, Voogd AC, Coebergh JWW, Roumen RM, Nolthenius-Puylaert MCT, et al. Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 127:195-203 10.1007/s10549-010-1086-6
• Avoiding Axillary Treatment in Sentinel Lymph Node Micrometastases of Breast Cancer: A Prospective Analysis of Axillary or Distant Recurrence Cite
  Pernas S, Gil M, Benítez A, Bajen MT, Climent F, Pla MJ, et al. Avoiding Axillary Treatment in Sentinel Lymph Node Micrometastases of Breast Cancer: A Prospective Analysis of Axillary or Distant Recurrence. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2009; 17:772-777 10.1245/s10434-009-0804-y
• Comparable Survival Between pN0 Breast Cancer Patients Undergoing Sentinel Node Biopsy and Extensive Axillary Dissection: A Report From the Korean Breast Cancer Society Cite
  Moon H, Han W, Noh D. Comparable Survival Between pN0 Breast Cancer Patients Undergoing Sentinel Node Biopsy and Extensive Axillary Dissection: A Report From the Korean Breast Cancer Society. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1692-1699 10.1200/jco.2009.25.9226
• Breast Cancer Prognosis and Occult Lymph Node Metastases, Isolated Tumor Cells, and Micrometastases Cite
  de Boer M, van Dijck JAAM, Bult P, Borm GF, Tjan-Heijnen VCG. Breast Cancer Prognosis and Occult Lymph Node Metastases, Isolated Tumor Cells, and Micrometastases. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:410-425 10.1093/jnci/djq008
• Indications for Sentinel Lymph Node Biopsy in the Setting of Prophylactic Mastectomy Cite
  Laronga C, Lee MC, McGuire KP, Meade T, Carter WB, Hoover S, et al. Indications for Sentinel Lymph Node Biopsy in the Setting of Prophylactic Mastectomy. Journal of the American College of Surgeons. Elsevier BV; 2009; 209:746-752 10.1016/j.jamcollsurg.2009.08.010
• The prognostic impact of occult nodal metastasis in early breast carcinoma Cite
  Park D, Kåresen R, Naume B, Synnestvedt M, Beraki E, Sauer T. The prognostic impact of occult nodal metastasis in early breast carcinoma. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 118:57-66 10.1007/s10549-009-0340-2
• Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases Cite
  Aitken S, Thomas J, Langdon S, Harrison D, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Annals of Oncology. Elsevier BV; 2010; 21:1254-1261 10.1093/annonc/mdp427
• The identification and treatment of isolated tumor cells reflect disparities in the delivery of breast cancer care Cite
  Tan JT, Bagnell M, Morgan JW, Wong JH, Roy-Chowdhury S, Lum SS. The identification and treatment of isolated tumor cells reflect disparities in the delivery of breast cancer care. The American Journal of Surgery. Elsevier BV; 2009; 198:508-510 10.1016/j.amjsurg.2009.07.001